Abstract:Background: Neoadjuvant radiotherapy has been used as the standard treatment of colorectal cancer (CRC). However, radiotherapy resistance often results in treatment failure. To identify radioresistant genes will provide novel targets for combined treatments and prognostic markers. Methods: Through high content screening and tissue array from CRC patients who are resistant or sensitive to radiotherapy, we identified a potent resistant gene SUMO specific peptidase 5 (SENP5). Then, the effect of SENP5 on radiosensitivity was investigated by CCK8, clone formation, comet assay, immunofluorescence and flow cytometric analysis of apoptosis and cell cycle to investigate the effect of SENP5 on radiosensitivity. SUMO-proteomic mass spectrometry combined with co-immunoprecipitation assay were used to identify the targets of SENP5. Patient-derived organoids (PDO) and xenograft (PDX) models were used to explore the possibility of clinical application. Results: We identified SENP5 as a potent radioresistant gene through high content screening and CRC patients tissue array analysis. Patients with high SENP5 expression showed increased resistance to radiotherapy. In vitro and in vivo experiments demonstrated that SENP5 knockdown significantly increased radiosensitivity in CRC cells. SENP5 was further demonstrated essential for efficient DNA damage repair in homologous recombination (HR) dependent manner. Through SUMO mass spectrometry analysis, we characterized H2AZ as a deSUMOylation substrate of SENP5, and depicted the SUMOylation balance of H2AZ in HR repair and cancer resistance. By using PDO and PDX models, we found targeting SENP5 significantly increased the therapeutic efficacy of radiotherapy. Conclusion: Our findings revealed novel role of SENP5 in HR mediated DNA damage repair and cancer resistance, which could be applied as potent prognostic marker and intervention target for cancer radiotherapy.

The SUMO-specific protease family regulates cancer cell radiosensitivity

SUMOylation Plays a Role in Gemcitabine- and Bortezomib-Induced Cytotoxicity in Human Oropharyngeal Carcinoma KB Gemcitabine-Resistant Clone.

SUMO-specific Protease 1 Regulates the in Vitro and in Vivo Growth of Colon Cancer Cells with the Upregulated Expression of CDK Inhibitors.

[Sumo-Specific Protease 1 and Cancer].

The Role of SUMO E3 Ligases in Signaling Pathway of Cancer Cells

Post-Translational Modification of SUMOylation and Cancer: A Brief Review

Roles of SUMOylation and De-Sumoylation in Carcinogenesis

Role of SUMO activating enzyme in cancer stem cell maintenance and self-renewal

The Critical Roles of the SUMO-Specific Protease SENP3 in Human Diseases and Clinical Implications

Emerging role of SENP1 in tumorigenesis and cancer therapy

SUMOylation Homeostasis in Tumorigenesis

SUMO‐specific proteases: SENPs in oxidative stress‐related signaling and diseases

SENP5 promotes homologous recombination-mediated DNA damage repair in colorectal cancer cells through H2AZ deSUMOylation

SENP1 Decreases RNF168 Phase Separation to Promote DNA Damage Repair and Drug Resistance in Colon Cancer.

SUMO and the robustness of cancer

The Emerging Roles of SUMOylation in the Tumor Microenvironment and Therapeutic Implications

The post-translational modification, SUMOylation, and cancer (Review)

SUMO-specific Protease 1 Promotes Prostate Cancer Progression and Metastasis.

SUMOylation Stabilizes Hssb1 and Enhances the Recruitment of NBS1 to DNA Damage Sites

Role of Desumoylation in the Development of Prostate Cancer

SUMO proteases: from cellular functions to disease